IPO13 and non-small cell lung carcinoma: Furthermore, suppression of EGFR signaling by Osimertinib (Tagrisso, AZD9291), a third-generation-irreversible EGFR-TK inhibitor with a high affinity for EGFR-mutant protein47,48, resulted in the inhibition of IPO13 expression in the EGFR-mutant NSCLC cell line, H1975 cell line, which harbors L858R mutation (exon 21) and T790M mutation (exon 20)30.